Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13295361 | 1.00 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13295357 | 1.00 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13295359 | 1.00 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13295360 | 1.00 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19604527 | 1.00 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25009658 | 0.86 | OPRM1 (0.34) | OPRM1APLNR | |
| SCHEMBL12418402 | 0.86 | OPRM1 (0.34) | OPRM1APLNR | |
| SCHEMBL10094034 | 0.86 | OPRM1 (0.34) | OPRM1APLNR | |
| SCHEMBL13313072 | 0.86 | OPRM1 (0.34) | OPRM1APLNR | |
| SCHEMBL12418401 | 0.86 | OPRM1 (0.34) | OPRM1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692289-A1 | PERFUME COMPOSITION AND ALICYCLIC ALCOHOL COMPOSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024203570-A1 | PERFUME COMPOSITION AND ALICYCLIC ALCOHOL COMPOSITION | 三菱瓦斯化学株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-20230265091-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-20140088087-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569287-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ESR1 2409/4885ESR2 2114/4885CYP3A4 3216/4885 |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | ESR1 1819/4885ESR2 2900/4885CYP3A4 1768/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | ESR1 2409/4885ESR2 2114/4885CYP3A4 3216/4885 |
| US-20230265091-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | POLR2E, POLR2H, POLRMT | ESR1 3280/4885ESR2 3791/4885CYP3A4 3712/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | ESR1 1745/4885ESR2 1727/4885CYP3A4 312/4885 |
| US-20140088087-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | ESR1 1745/4885ESR2 1727/4885CYP3A4 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.